

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO  
SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **April 29, 2010**

**BECTON, DICKINSON AND COMPANY**

---

(Exact Name of Registrant as Specified in Its Charter)

---

**New Jersey**

---

(State or Other Jurisdiction of Incorporation)

---

**001-4802**

---

(Commission File Number)

---

**22-0760120**

---

(IRS Employer Identification No.)

---

**1 Becton Drive, Franklin Lakes, New Jersey**

---

(Address of Principal Executive Offices)

---

**07417-1880**

---

(Zip Code)

---

**(201) 847-6800**

---

(Registrant's Telephone Number, Including Area Code)

---

**N/A**

---

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

## ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On April 29, 2010, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its second fiscal quarter ending March 31, 2010. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”), as follows:

- Revenues. We present international and total revenue growth rates (for the total company and each of its segments and business units, and revenues relating to our safety-engineered devices) for the second quarter and first six months of fiscal year 2010 after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that this allows investors to better understand the underlying operating results of BD and facilitates comparisons to prior periods.
- Earnings Per Share from Continuing Operations. We present our diluted earnings per share from continuing operations (“EPS”) for the second quarter and first six months of fiscal year 2010 after eliminating the non-cash charge related to health care reform impacting Medicare Part D reimbursements. We also present our EPS for the second quarter and first six months of fiscal year 2009 after excluding the impact of the charge relating to our pending settlement of certain antitrust class action suits (the “Litigation Charge”), and our EPS for the full 2009 fiscal year after excluding the Litigation Charge and the tax benefit relating to various tax settlements. These items are not considered by management to be part of ordinary operations. Accordingly, we believe that these adjusted measures of EPS are more indicative of BD’s underlying performance for these periods, and allow investors to more easily compare BD’s performance for these periods and to better understand BD’s EPS guidance for fiscal year 2010.

We also present our growth in adjusted EPS for the second quarter and first six months of fiscal year 2010, and our adjusted EPS guidance for the full 2010 fiscal year, after eliminating the effect of foreign currency translation, including gains or losses from our hedging activities. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and facilitates comparisons to the prior year periods.

BD’s management uses each of these non-GAAP measures in its own evaluation of BD’s performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD’s financial results. Management believes the non-GAAP results provide a reasonable measure of BD’s underlying performance before the effects of items that are considered by management to be outside of BD’s underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD’s management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD’s net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD’s results.

---

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated April 29, 2010, which is furnished pursuant to Item 2.02

Exhibit 99.2 Reconciliation of non-GAAP financial measures, which is furnished pursuant to Item 2.02

---

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY  
(Registrant)

By: /s/ Dean J. Parnicas  
Dean J. Parnicas  
Vice President, Corporate  
Secretary and Public Policy

Date: April 29, 2010

---

Exhibit Index

- 99.1 Press release dated April 29, 2010, furnished pursuant to Item 2.02
- 99.2 Reconciliation of non-GAAP financial measures, furnished pursuant to Item 2.02

1 Becton Drive  
Franklin Lakes, NJ 07417  
www.bd.com

News Release



Contact:

Sherry L. Bertner, Investor Relations – 201-847-5453  
Colleen T. White, Corporate Communications – 201-847-5369

**BD ANNOUNCES RESULTS FOR SECOND QUARTER FISCAL 2010**

- Reports earnings per share from continuing operations of \$1.24, or \$1.27 after excluding specified item
- Reaffirms guidance for full-year fiscal 2010 earnings per share from continuing operations, excluding specified items

**Franklin Lakes, NJ (April 29, 2010)**– BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of \$1.845 billion for the second fiscal quarter ended March 31, 2010, representing an increase of 7.0 percent from the prior-year period, or 6.6 percent on a foreign currency-neutral basis.

“We are pleased with our second quarter results, which are in line with the Company’s expectations,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “Solid revenue growth in our Medical segment and a continued improvement in our Biosciences segment offset lower than expected growth in our Diagnostics segment. Our strong overall operating performance for the first half of fiscal 2010 gives us the confidence to reaffirm our guidance for full-year adjusted earnings.”

---

### **Second Quarter and Six-Month Fiscal 2010 Operating Results**

Reported diluted earnings per share from continuing operations for the second quarter were \$1.24 compared with \$1.05 in the prior-year period. Current quarter results included a non-cash charge of \$8.9 million, or \$0.04 per share from continuing operations related to healthcare reform impacting Medicare Part D reimbursements, and the prior-year period included a litigation charge of \$45 million, or \$0.11 per share. Excluding these items, adjusted diluted earnings per share from continuing operations increased by 8.5 percent to \$1.27, compared with \$1.17 adjusted earnings per share in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the second quarter increased by 16.2 percent.

For the six-month period ending March 31, 2010, reported diluted earnings per share from continuing operations were \$2.53 compared with \$2.30 in the prior-year period. Excluding the aforementioned charges, diluted earnings per share from continuing operations were \$2.57, an increase of 6.6 percent over adjusted diluted earnings per share from continuing operations of \$2.41 in the prior-year period. On a foreign currency-neutral basis, adjusted diluted earnings per share from continuing operations for the six-month period increased 14.1 percent.

### **Segment Results**

In the BD Medical segment, worldwide revenues for the quarter were \$967 million, representing an increase of 9.7 percent compared with the prior-year period, or 7.8 percent on a foreign currency-neutral basis. Revenues reflect strong sales of Diabetes Care and Pharmaceutical Systems products. For the six-month period ended March 31, 2010, BD Medical revenues increased 13.0 percent, or 10.2 percent on a foreign currency-neutral basis.

---

In the BD Diagnostics segment, worldwide revenues for the quarter were \$556 million, representing an increase of 3.0 percent compared with the prior-year period. Segment revenues increased 2.7 percent on a foreign currency-neutral basis, impacted by a reduction in lab testing and a decline in flu-related testing due to an exceptionally mild flu season. These were offset by strong growth in cancer and STD product platforms. For the six-month period ended March 31, 2010, BD Diagnostics revenues increased 6.6 percent, or 5.4 percent on a foreign currency-neutral basis.

In the BD Biosciences segment, worldwide revenues for the quarter were \$322 million, representing an increase of 6.0 percent compared with the prior-year period. Revenues increased 9.8 percent on a foreign currency-neutral basis, driven by Cell Analysis and Discovery Labware growth in certain markets. For the six-month period ended March 31, 2010, BD Biosciences revenues increased by 3.0 percent, or 5.2 percent on a foreign currency-neutral basis.

#### **Geographic Results**

Second quarter revenues in the U.S. were \$810 million, representing an increase of 6.0 percent from the prior-year period. Revenues outside of the U.S. were \$1.035 billion, representing an increase of 7.7 percent compared with the prior-year period, or 7.0 percent on a foreign currency-neutral basis.

For the six-month period ended March 31, 2010, revenues in the U.S. were \$1.683 billion, representing an increase of 7.9 percent compared with the prior-year period. Revenues outside of the U.S. were \$2.078 billion, representing an increase of 10.4 percent compared with the prior-year period, or 7.8 percent on a foreign currency-neutral basis.

---



**Fiscal 2010 Outlook**

We expect reported revenues for the full year fiscal 2010 to increase approximately 6 percent, or about 1 percent less than our previously communicated guidance due to currency fluctuations. On a foreign currency-neutral basis, we expect revenues to increase approximately 6 percent, which is in line with our previously communicated guidance.

We also expect reported diluted earnings per share from continuing operations for the full year fiscal 2010 to be \$5.01 to \$5.11. Excluding the aforementioned charge of \$0.04 related to healthcare reform impacting Medicare Part D reimbursements, we reaffirm our guidance that we expect diluted earnings per share from continuing operations for the full year fiscal 2010 will increase approximately 2 to 4 percent to \$5.05 to \$5.15, or 8 to 10 percent on a foreign currency-neutral basis. This is compared to adjusted diluted earnings per share from continuing operations, excluding the litigation charge of \$0.11 and a tax benefit adjustment of \$0.08, of \$4.95 for fiscal year 2009. Reported diluted earnings per share from continuing operations for fiscal year 2009 were \$4.92.

**Conference Call Information**

A conference call regarding BD's second quarter results and its expectations for the full fiscal year will be broadcast live on BD's website [www.bd.com/investors](http://www.bd.com/investors), along with related slides, at 10:00 a.m. (ET) Thursday, April 29, 2010. The conference call will be available for replay on BD's website, [www.bd.com/investors](http://www.bd.com/investors), or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international) through the close of business on May 6, 2010, access code 67104728.

---

### **Non-GAAP Financial Measures**

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables and the Form 8-K that BD filed today with the SEC.

### **About BD**

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in more than 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit [www.bd.com](http://www.bd.com).

\*\*\*

*This press release contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. These factors include, but are not limited to: the unknown consequences of the recently-enacted healthcare reform in the United States, including the impact of the reduction in Medicare and Medicaid payments to hospitals, pharmaceutical companies and other customers, which could reduce demand for our products and increase downward pricing pressure; adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products*

---

*needed for our operations; changes in interest or foreign currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.*

---

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2010	Three Months Ended March 31, 2009	% Change
<b>REVENUES</b>	<b>\$1,844,854</b>	<b>\$1,724,967</b>	<b>7.0</b>
Cost of products sold	886,895	829,350	6.9
Selling and administrative	426,346	436,359	(2.3)
Research and development	101,118	98,588	2.6
<b>TOTAL OPERATING COSTS AND EXPENSES</b>	<b>1,414,359</b>	<b>1,364,297</b>	<b>3.7</b>
<b>OPERATING INCOME</b>	<b>430,495</b>	<b>360,670</b>	<b>19.4</b>
Interest income	9,652	4,312	NM
Interest expense	(12,913)	(7,495)	72.3
Other income (expense), net	164	(5,701)	NM
<b>INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES</b>	<b>427,398</b>	<b>351,786</b>	<b>21.5</b>
Income tax provision	129,673	92,612	40.0
<b>INCOME FROM CONTINUING OPERATIONS</b>	<b>297,725</b>	<b>259,174</b>	<b>14.9</b>
<b>(LOSS) INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX (BENEFIT) PROVISION OF \$(54) AND \$611, RESPECTIVELY</b>	<b>(94)</b>	<b>2,115</b>	<b>NM</b>
<b>NET INCOME</b>	<b>\$ 297,631</b>	<b>\$ 261,289</b>	<b>13.9</b>
<b>EARNINGS PER SHARE</b>			
Basic:			
Income from continuing operations	\$ 1.27	\$ 1.08	17.6
(Loss) income from discontinued operations	\$ —	\$ 0.01	NM
Net income (1)	\$ 1.26	\$ 1.09	15.6
Diluted:			
Income from continuing operations	\$ 1.24	\$ 1.05	18.1
(Loss) income from discontinued operations	\$ —	\$ 0.01	NM
Net income	\$ 1.24	\$ 1.06	17.0
<b>AVERAGE SHARES OUTSTANDING</b>			
Basic	235,325	240,239	
Diluted	240,863	245,890	

NM – Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY  
CONSOLIDATED INCOME STATEMENTS  
(Unaudited; Amounts in thousands, except per share data)

	2010	Six Months Ended March 31, 2009	% Change
REVENUES	\$3,761,628	\$3,442,886	9.3
Cost of products sold	1,806,437	1,625,624	11.1
Selling and administrative	877,275	842,378	4.1
Research and development	201,402	195,902	2.8
TOTAL OPERATING COSTS AND EXPENSES	2,885,114	2,663,904	8.3
OPERATING INCOME	876,514	778,982	12.5
Interest income	18,441	5,963	NM
Interest expense	(25,900)	(15,319)	69.1
Other (expense) income, net	(2,189)	3,710	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	866,866	773,336	12.1
Income tax provision	253,163	204,743	23.6
INCOME FROM CONTINUING OPERATIONS	613,703	568,593	7.9
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$99 AND \$1,465, RESPECTIVELY	304	4,764	NM
NET INCOME	\$ 614,007	\$ 573,357	7.1
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 2.60	\$ 2.36	10.2
Income from discontinued operations	\$ —	\$ 0.02	NM
Net income	\$ 2.60	\$ 2.38	9.2
Diluted:			
Income from continuing operations	\$ 2.53	\$ 2.30	10.0
Income from discontinued operations	\$ —	\$ 0.02	NM
Net income	\$ 2.53	\$ 2.32	9.1
AVERAGE SHARES OUTSTANDING			
Basic	236,353	241,330	
Diluted	242,327	247,436	

NM – Not Meaningful

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2010	Three Months Ended March 31, 2009	% Change
<b>BD MEDICAL</b>			
United States	\$ 400,241	\$ 375,003	6.7
International	566,837	506,484	11.9
<b>TOTAL</b>	<b>\$ 967,078</b>	<b>\$ 881,487</b>	<b>9.7</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 292,841	\$ 285,113	2.7
International	262,831	254,527	3.3
<b>TOTAL</b>	<b>\$ 555,672</b>	<b>\$ 539,640</b>	<b>3.0</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 117,151	\$ 104,039	12.6
International	204,953	199,801	2.6
<b>TOTAL</b>	<b>\$ 322,104</b>	<b>\$ 303,840</b>	<b>6.0</b>
<b>TOTAL REVENUES</b>			
United States	\$ 810,233	\$ 764,155	6.0
International	1,034,621	960,812	7.7
<b>TOTAL</b>	<b>\$1,844,854</b>	<b>\$1,724,967</b>	<b>7.0</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY SEGMENT AND GEOGRAPHIC AREA  
(Unaudited; Amounts in thousands)

	2010	Six Months Ended March 31, 2009	% Change
<b>BD MEDICAL</b>			
United States	\$ 852,627	\$ 769,165	10.9
International	1,133,077	987,512	14.7
<b>TOTAL</b>	<b>\$1,985,704</b>	<b>\$1,756,677</b>	<b>13.0</b>
<b>BD DIAGNOSTICS</b>			
United States	\$ 603,045	\$ 572,681	5.3
International	548,102	507,150	8.1
<b>TOTAL</b>	<b>\$1,151,147</b>	<b>\$1,079,831</b>	<b>6.6</b>
<b>BD BIOSCIENCES</b>			
United States	\$ 227,787	\$ 217,790	4.6
International	396,990	388,588	2.2
<b>TOTAL</b>	<b>\$ 624,777</b>	<b>\$ 606,378</b>	<b>3.0</b>
<b>TOTAL REVENUES</b>			
United States	\$1,683,459	\$1,559,636	7.9
International	2,078,169	1,883,250	10.4
<b>TOTAL</b>	<b>\$3,761,628</b>	<b>\$3,442,886</b>	<b>9.3</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2010	2009	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$248,601	\$242,350	2.6
Diabetes Care	92,515	83,233	11.2
Pharmaceutical Systems	52,078	43,065	20.9
Ophthalmic Systems	7,047	6,355	10.9
<b>TOTAL</b>	<b>\$400,241</b>	<b>\$375,003</b>	<b>6.7</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$149,932	\$147,436	1.7
Diagnostic Systems	142,909	137,677	3.8
<b>TOTAL</b>	<b>\$292,841</b>	<b>\$285,113</b>	<b>2.7</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 78,183	\$ 71,770	8.9
Discovery Labware	38,968	32,269	20.8
<b>TOTAL</b>	<b>\$117,151</b>	<b>\$104,039</b>	<b>12.6</b>
<b>TOTAL UNITED STATES</b>	<b>\$810,233</b>	<b>\$764,155</b>	<b>6.0</b>



BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	International		
			Reported	% Change FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 257,488	\$230,233	11.8	6.6	5.2
Diabetes Care	95,471	85,159	12.1	9.3	2.8
Pharmaceutical Systems	200,305	178,085	12.5	11.1	1.4
Ophthalmic Systems	13,573	13,007	4.4	5.9	(1.5)
<b>TOTAL</b>	<b>\$ 566,837</b>	<b>\$506,484</b>	<b>11.9</b>	<b>8.6</b>	<b>3.3</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 137,738	\$131,029	5.1	3.1	2.0
Diagnostic Systems	125,093	123,498	1.3	2.4	(1.1)
<b>TOTAL</b>	<b>\$ 262,831</b>	<b>\$254,527</b>	<b>3.3</b>	<b>2.8</b>	<b>0.5</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 164,292	\$159,223	3.2	9.1	(5.9)
Discovery Labware	40,661	40,578	0.2	5.8	(5.6)
<b>TOTAL</b>	<b>\$ 204,953</b>	<b>\$199,801</b>	<b>2.6</b>	<b>8.4</b>	<b>(5.8)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$1,034,621</b>	<b>\$960,812</b>	<b>7.7</b>	<b>7.0</b>	<b>0.7</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Three Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	Total		
			Reported	% Change	
				FXN	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 506,089	\$ 472,583	7.1	4.6	2.5
Diabetes Care	187,986	168,392	11.6	10.2	1.4
Pharmaceutical Systems	252,383	221,150	14.1	13.0	1.1
Ophthalmic Systems	20,620	19,362	6.5	7.5	(1.0)
<b>TOTAL</b>	<b>\$ 967,078</b>	<b>\$ 881,487</b>	<b>9.7</b>	<b>7.8</b>	<b>1.9</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 287,670	\$ 278,465	3.3	2.4	0.9
Diagnostic Systems	268,002	261,175	2.6	3.1	(0.5)
<b>TOTAL</b>	<b>\$ 555,672</b>	<b>\$ 539,640</b>	<b>3.0</b>	<b>2.7</b>	<b>0.3</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 242,475	\$ 230,993	5.0	9.0	(4.0)
Discovery Labware	79,629	72,847	9.3	12.4	(3.1)
<b>TOTAL</b>	<b>\$ 322,104</b>	<b>\$ 303,840</b>	<b>6.0</b>	<b>9.8</b>	<b>(3.8)</b>
<b>TOTAL REVENUES</b>	<b>\$1,844,854</b>	<b>\$1,724,967</b>	<b>7.0</b>	<b>6.6</b>	<b>0.4</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31,  
(Unaudited; Amounts in thousands)

	United States		% Change
	2010	2009	
<b>BD MEDICAL</b>			
Medical Surgical Systems	\$ 535,136	\$ 498,605	7.3
Diabetes Care	189,079	171,699	10.1
Pharmaceutical Systems	114,099	85,717	33.1
Ophthalmic Systems	14,313	13,144	8.9
<b>TOTAL</b>	<b>\$ 852,627</b>	<b>\$ 769,165</b>	<b>10.9</b>
<b>BD DIAGNOSTICS</b>			
Preanalytical Systems	\$ 306,167	\$ 296,666	3.2
Diagnostic Systems	296,878	276,015	7.6
<b>TOTAL</b>	<b>\$ 603,045</b>	<b>\$ 572,681</b>	<b>5.3</b>
<b>BD BIOSCIENCES</b>			
Cell Analysis	\$ 155,787	\$ 149,150	4.4
Discovery Labware	72,000	68,640	4.9
<b>TOTAL</b>	<b>\$ 227,787</b>	<b>\$ 217,790</b>	<b>4.6</b>
<b>TOTAL UNITED STATES</b>	<b>\$1,683,459</b>	<b>\$1,559,636</b>	<b>7.9</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	International		
			Reported	% Change FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$ 530,976	\$ 454,480	16.8	10.9	5.9
Diabetes Care	200,428	176,699	13.4	8.5	4.9
Pharmaceutical Systems	374,258	330,214	13.3	9.3	4.0
Ophthalmic Systems	27,415	26,119	5.0	4.3	0.7
<b>TOTAL</b>	<b>\$1,133,077</b>	<b>\$ 987,512</b>	<b>14.7</b>	<b>9.8</b>	<b>4.9</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 281,670	\$ 259,953	8.4	4.9	3.5
Diagnostic Systems	266,432	247,197	7.8	6.2	1.6
<b>TOTAL</b>	<b>\$ 548,102</b>	<b>\$ 507,150</b>	<b>8.1</b>	<b>5.5</b>	<b>2.6</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 318,025	\$ 311,364	2.1	5.6	(3.5)
Discovery Labware	78,965	77,224	2.3	5.4	(3.1)
<b>TOTAL</b>	<b>\$ 396,990</b>	<b>\$ 388,588</b>	<b>2.2</b>	<b>5.5</b>	<b>(3.3)</b>
<b>TOTAL INTERNATIONAL</b>	<b>\$2,078,169</b>	<b>\$1,883,250</b>	<b>10.4</b>	<b>7.8</b>	<b>2.6</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
REVENUES BY BUSINESS SEGMENTS AND UNITS  
Six Months Ended March 31, (continued)  
(Unaudited; Amounts in thousands)

	2010	2009	Total		
			Reported	% Change FX Neutral	FX Impact
<b>BD MEDICAL</b>					
Medical Surgical Systems	\$1,066,112	\$ 953,085	11.9	9.0	2.9
Diabetes Care	389,507	348,398	11.8	9.3	2.5
Pharmaceutical Systems	488,357	415,931	17.4	14.2	3.2
Ophthalmic Systems	41,728	39,263	6.3	5.9	0.4
<b>TOTAL</b>	<b>\$1,985,704</b>	<b>\$1,756,677</b>	<b>13.0</b>	<b>10.2</b>	<b>2.8</b>
<b>BD DIAGNOSTICS</b>					
Preanalytical Systems	\$ 587,837	\$ 556,619	5.6	4.0	1.6
Diagnostic Systems	563,310	523,212	7.7	6.9	0.8
<b>TOTAL</b>	<b>\$1,151,147</b>	<b>\$1,079,831</b>	<b>6.6</b>	<b>5.4</b>	<b>1.2</b>
<b>BD BIOSCIENCES</b>					
Cell Analysis	\$ 473,812	\$ 460,514	2.9	5.2	(2.3)
Discovery Labware	150,965	145,864	3.5	5.1	(1.6)
<b>TOTAL</b>	<b>\$ 624,777</b>	<b>\$ 606,378</b>	<b>3.0</b>	<b>5.2</b>	<b>(2.2)</b>
<b>TOTAL REVENUES</b>	<b>\$3,761,628</b>	<b>\$3,442,886</b>	<b>9.3</b>	<b>7.8</b>	<b>1.5</b>

BECTON DICKINSON AND COMPANY  
SUPPLEMENTAL REVENUE INFORMATION  
SAFETY REVENUES  
(Unaudited; Amounts in thousands)

	Three Months Ended March 31,				
	2010	2009	Reported	% Change FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$268,773	\$255,026	5.4	5.4	—
International	149,475	136,718	9.3	6.8	2.5
<b>TOTAL</b>	<b>\$418,248</b>	<b>\$391,744</b>	<b>6.8</b>	<b>5.9</b>	<b>0.9</b>
<b>BY SEGMENT</b>					
BD Medical	\$200,355	\$183,591	9.1	8.0	1.1
BD Diagnostics	217,893	208,153	4.7	4.0	0.7
<b>TOTAL</b>	<b>\$418,248</b>	<b>\$391,744</b>	<b>6.8</b>	<b>5.9</b>	<b>0.9</b>

	Six Months Ended March 31,				
	2010	2009	Reported	% Change FXN	FX Impact
<b>TOTAL SAFETY REVENUES</b>					
United States	\$567,031	\$523,995	8.2	8.2	—
International	305,489	270,798	12.8	8.6	4.2
<b>TOTAL</b>	<b>\$872,520</b>	<b>\$794,793</b>	<b>9.8</b>	<b>8.4</b>	<b>1.4</b>
<b>BY SEGMENT</b>					
BD Medical	\$428,857	\$376,342	14.0	12.3	1.7
BD Diagnostics	443,663	418,451	6.0	4.8	1.2
<b>TOTAL</b>	<b>\$872,520</b>	<b>\$794,793</b>	<b>9.8</b>	<b>8.4</b>	<b>1.4</b>

**Reconciliations of non-GAAP financial measures**  
**(All figures are rounded. Totals may not add up due to rounding)**

**Second quarter and first six months fiscal year (“FY”) 2009 adjusted diluted earnings per share from continuing operations (“EPS”)**

	<u>Second Quarter</u>	<u>First Six Months</u>
Reported EPS	\$ 1.05	\$ 2.30
Litigation charge (1)	\$ 0.11	\$ 0.11
Adjusted EPS	\$ 1.17	\$ 2.41

(1) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in the antitrust class actions.

**Second quarter and first six months FY 2010 adjusted EPS**

	<u>Second Quarter</u>	<u>First Six Months</u>
Reported EPS	\$ 1.24	\$ 2.53
Tax charge (1)	\$ 0.04	\$ 0.04
Adjusted EPS	\$ 1.27	\$ 2.57

(1) Represents the charge related to health care reform impacting Medicare Part D reimbursements.

**Full year FY 2009 adjusted EPS**

Reported EPS	\$ 4.92
Litigation charge (1)	\$ 0.11
Tax adjustment (2)	\$ (0.08)
Adjusted EPS	\$ 4.95

(1) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in the antitrust class actions.

(2) Represents the tax benefit relating to various tax settlements in multiple jurisdictions.

---

**Second quarter FY2010 foreign currency-neutral EPS growth**

	Q2 FY2010	Q2 FY2009	Change (\$)	Q2 FY2009 foreign currency holding gain	Impact of foreign currency translation	Q2 FY2010 foreign currency holding loss	Total unfavorable foreign currency impact	Foreign currency neutral growth (\$)	Foreign currency neutral growth (%)
Adjusted EPS	\$ 1.27	\$ 1.17	\$0.10	(0.08)	0.06	(0.07)	(0.09)	0.19	16.2%

**First six months FY2010 foreign currency-neutral EPS growth**

	FY2010	FY2009	Change (\$)	FY2009 foreign currency holding gain	FY2009 foreign currency holding gain	Impact of foreign currency translation	FY2010 foreign currency holding loss	Total unfavorable foreign currency impact	Foreign currency neutral growth (\$)	Foreign currency neutral growth (%)
Adjusted EPS	\$ 2.57	\$ 2.41	\$0.16	(0.09)	(0.16)	0.19	(0.11)	(0.18)	0.34	14.1%

**FY 2010 EPS Outlook**

	Estimated growth (based on adjusted FY2009 EPS of \$4.95)	Estimated foreign currency neutral growth	Estimated impact of foreign currency translation
EPS guidance — reported	\$ 5.01-\$5.11	1-3%	7-9%
Tax charge (1)	\$ .04	1%	1%
EPS guidance — as adjusted	\$ 5.05-\$5.15	2-4%	8-10%

(1) Represents impact of charge related to health care reform impacting Medicare Part D reimbursements.

The FY2010 impact of -6% represents the year-on-year change due to estimated foreign currency translation, including hedging activities, as follows:

<b>FY2009 Items:</b>	
Actual hedge gain in FY2009	\$ (0.26)
Q1 FY2009 foreign currency holding gain	\$ (0.09)
<b>FY2010 Activity: *</b>	
Estimated effect of foreign currency translation	\$ 0.17
Estimated hedge losses	\$ (0.12)
<b>Total Year-on-Year Impact</b>	<b>\$ (0.30)</b>
Impact on EPS Growth	\$ (0.30)/\$4.95 ~ -6%

\* Estimated impact is based on the foreign exchange rates established for BD's most recent fiscal year 2010 projection.